A safe and highly efficient antiviral is needed for the prophylaxis and/or treatment of viral diarrhea. We here demonstrate the in vitro antiviral activity of four 2′-C-methyl nucleoside analogues against noro-, rota-, and sapoviruses. The most potent nucleoside analogue, 7-deaza-2′-C-methyladenosine, inhibits replication of these viruses with a 50% effective concentration < 5 µM. Mechanistically, we demonstrate that the 2′-C-methyl nucleoside analogues act by inhibiting transcription of the rotavirus genome. This provides the first evidence that a single viral-diarrhea-targeted treatment can be developed through a viral-polymerase-targeting small molecule.
Diarrhea is one of the most important causes of childhood mortality worldwide [1] . Rotaviruses (Reoviridae, 11-segmented double-stranded RNA [dsRNA] ) are the most important viral cause of childhood diarrhea. Since 2 vaccines were introduced, the estimated number of rotavirus-caused mortality has declined to approximately 215 000 in 2013 [2] . The World Health Organization (WHO) estimates that the global coverage of rotavirus vaccination is approximately 25%, being particularly low in developing countries. Noroviruses (Caliciviridae, positive-sense single-stranded RNA [(+) ssRNA]) are the second most important viral cause of childhood diarrhea, resulting in approximately 200 000 deaths/year [3] . Efforts to develop a norovirus vaccine are ongoing (GI.1/ GII.4 vaccine by Takeda and oral vaccine by Vaxart). In immunocompromised patients, mostly following organ transplantation, chronic rota-and norovirus infections can occur. Other viruses that may cause diarrhea in children are human adenovirus (Adenoviridae, dsDNA), sapovirus (Caliciviridae, (+) ssRNA), and astrovirus (Astroviridae, (+)ssRNA). No specific antivirals are available against viral diarrhea, only supportive therapy with oral rehydration salts. The WHO recommends zinc supplementation, although the effect is not equal for every causative agent and its antidiarrheal effect is not fully understood [4] . Nitazoxanide, an antiprotozoal drug, has activity against Giardia, Cryptosporidium parvum, multiple bacteria, and some activity against rota-and norovirus [5] [6] [7] . Valopicitabine, the 3′-valyl ester oral prodrug of the nucleoside analogue 2′-C-methylcytidine (2CMC) was shown to reduce viral loads in patients chronically infected with hepatitis C virus (HCV) and we demonstrated antiviral activity both in vitro and in vivo against noroviruses [8] [9] [10] . It is difficult to identify the causative agent of viral diarrhea based on clinical symptoms, but starting specific treatment early would grant a higher chance of success. Therefore we aimed to identify one inhibitor that is effective against multiple viral diarrhea-causing viruses. The catalytic site of the RNA-dependent RNA polymerases (RdRps) of RNA viruses is located in the palm domain and is highly conserved; antivirals targeting this site may have the potential to exert broad-spectrum activity (Supplementary Figure 1) . We here assessed the potential antiviral activity of four 2′-C-methyl nucleosides (Supplementary Figure 2) (2CMC, 2′-C-methyladenosine
[2CMA], 2′-C-methylguanosine [2CMG], and 7-deaza-2′-C-methyladenosine [7DMA]) against noro-, rota-, and sapovirus.
MATERIALS AND METHODS

Viruses and Cells
Murine norovirus (MNV-1.CW1) was propagated as described earlier [9] . Porcine sapovirus (PSaV, Cowden strain), was propagated in LLC-PK1-BVDV-Npro cells supplemented with 100 μM glycochenodeoxycholic acid (GCDCA). The human rotavirus ST3 (RV-ST3) and simian rotavirus SA11 (RV-SA11) strains were propagated in MA104 cells. Prior to infection, RV-ST3 or RV-SA11 were preactivated (1 hour, 10 μg/mL porcine trypsin IX-S; Sigma-Aldrich). Upon infection, 1 μg/mL trypsin was used on the cell monolayer. Upon full cytopathic effect (CPE), cells underwent 2 freeze-thaw cycles; the virus was harvested from the supernatants, centrifuged, and stored at −80°C. Viral titers were determined by endpoint titration. Cells were maintained as described in Supplementary Methods.
Antiviral and Cytotoxicity Assay
Murine Norovirus and Human Norwalk Replicon
These experiments were performed as described in Supplementary Methods.
Rotavirus
MA104 cells (2 × 10
3 cells/well) were seeded in 96-well plates and infected the next day with preactivated RV (multiplicity of infection [MOI] 0.01) in serum-free media and treated with compound. After 3 days, the monolayers were fixed with 70% ethanol (1 hour), dried, and stained with 1% methylene blue. The monolayers were scored between 0 and 5 (normal morphology-complete CPE). The 50% effective concentration (EC 50 ) is the concentration that protected 50% of the cells from CPE. The cytotoxicity concentration (CC 50 ) was defined as the concentration that reduces cell viability by 50%; % cell viability was calculated as (OD treated /OD CC ) × 10.
Porcine Sapovirus
LLC-PK1-BVDV-NPro cells (1.5 × 10 4 cells/well) were seeded in 96-well plates. The next day, monolayers were infected with PSaV (MOI 1) and treated with compound. One hour postinfection (hpi), 100 μM of GCDCA was added and cells were incubated for 5 days. The EC 50 and CC 50 were determined using the MTS method.
Virus Yield Assay
The supernatants of treated or untreated infected cells were harvested and viral RNA was isolated (NucleoSpin RNA Virus Kit, Macherey-Nagel).
RT-qPCR
A one-step reverse transcription quantitative polymerase chain reaction (RT-qPCR) was performed with the iTaq Universal Probes or SYBR Green One-Step Kit (Bio-Rad) (Supplementary Methods, and Supplementary Table 2 ).
In Vitro Inhibition of Rotavirus Viroplasm Formation
MA104/NSP5-EGFP cells were seeded on a coverslip and infected with RV-SA11-4F (G3; P6 [1] , MOI 5) the next day. One hpi, cells were washed and treated with compound in serum-free Dulbecco's Modified Eagle's Medium. Six hpi, cells were washed with phosphate-buffered saline and fixed with 3.7% paraformaldehyde at room temperature for 10 minutes. Coverslips were washed and mounted with ProLong mounting medium (Molecular Probes, Life Technologies). The number of viroplasms, cytosolic inclusion bodies in the cell where viral replication and assembly occurs, were analyzed by confocal microscopy (Zeiss LSM510, 100X, numerical aperture 1.3 objective) and images were processed using LSM Image Examiner 4.0.
In Vitro Transcription Assays With Purified Rotavirus DLPs
Double-layered particles (DLPs) from the RV-SA11-4F (G3, P6 [1] ) strain were obtained from infected MA104 cells by CsCl gradient purification (using trichlorofluoromethane, Sigma, 1:1 ratio). One μg of purified DLPs was incubated (4 hours, 42°C) in a final volume of 100 μL of 1× T7 transcription buffer (Promega), 2 mM nucleoside triphosphate, 0.5 mM S-adenosyl methionine, 0.1 mM MnCl 2 , 1 mM dithiothreitol (DTT), 0.4 U RNAsin, in the presence or absence of compound. The synthesized transcripts were isolated, concentrated (GeneJET RNA Cleanup and Concentration Micro Kit, Thermo Fisher Scientific) and quantified (Qubit RNA Assay Kits and Qubit 2.0 Fluorometer, Thermo Fisher Scientific).
In Vitro Enzymatic Inhibition Assay With MNV RdRp
RdRp activity was assessed following the synthesis of dsRNA from a single-stranded poly(U) template (10 μg; Sigma-Aldrich, P9528) and 100 μM ATP, in a reaction mixture containing 20 mM Tris/HCl (pH 7.5), 1 mM DTT, 25 mM NaCl, 5 mM MgCl 2 , 0.3 mM MnCl 2 , 2U RiboLock Ribonuclease inhibitor (Life technologies), 1 μL PicoGreen Quantitation Reagent (Life technologies). MNV RdRp (3.4 μM) was added to the reaction mixture together with the compound. The fluorescence (excitation/emission = 485/530 nm) was measured at 30°C for 1 hour (TECAN Infinite 200 PRO). RdRp activity (linear slope of fluorescence increase in time) vs inhibitor concentrations was used to estimate the IC 50 of the compound using GraFit5 (Erithacus software) and Y = (Range/(1 + (X/IC 50 )s). Range is the value observed for the uninhibited RdRp, and s is a slope factor.
RESULTS
We explored the in vitro antiviral effect of 2CMC, 2CMA, 2CMG, and 7DMA, as well as that of tizoxanide (the active metabolite of nitazoxanide) on the replication of human and simian rotaviruses. Rotavirus-induced CPE was completely inhibited by 7DMA, 2CMC, and 2CMA, whereby 7DMA proved the most potent/selective ( Figure 1A and Supplementary Figure 3) . The antiviral effect was confirmed by detection of reduced virus yields. 2CMG was the least potent of the tested 2′-C-methyl nucleosides (Supplementary Table 1) . Tizoxanide was not able to reduce rotavirus-induced CPE (data not shown). 7DMA inhibited RV-ST3, RV-SA11, and the human Norwalk replicon with roughly the same antiviral potency but was less effective against MNV ( Figure 1B and Supplementary Figure 4) ; we previously reported the opposite for 2CMC [9] . Tizoxanide was also devoid of activity against MNV (toxic effects at 12.5 µM) and had limited selective activity against the Norwalk replicon (EC 50 6 ± 4 µM). A very moderate antirotavirus effect was observed with 25 and 50 µM of tizoxanide at 12 hpi, by fluorescent staining of VP6 in RV-ST3-infected cells (Supplementary Figure 5A) . However, this mostly disappeared at 24 hpi (Supplementary Figure 5B) . The antirotavirus activity of 7DMA and 2CMC was further confirmed in RV-SA11-infected NSP5-EGFP/MA104 cells. 7DMA proved the most potent and dose-dependently reduced the total number of viroplasms per cell (Figure 2A) .
To assess the potential activity against sapoviruses, PSaV was used because there is no in vitro replication system for HuSaV. 7DMA efficiently inhibited virus-induced CPE (EC 50 4 ± 2 µM) and viral RNA yields (EC 50 5 ± 3 µM), and no adverse effects were noted on LLC-PK1 cells up to 100 µM ( Figure 1C ). Compared to 7DMA, 2CMC proved approximately 5-fold less potent in CPE reduction (EC 50 22 ± 9 µM) and viral RNA reduction (EC 50 16 ± 3 µM).
To understand how 2′-C-methyl nucleosides inhibit rotavirus RNA replication, in vitro transcription assays were performed with double-layered particles (DLPs, containing the active polymerase-capping enzyme complex VP1-VP3) purified from RV-SA11-infected cells. Transcription inhibition was assessed by direct competition of the 5′ triphosphate of 2CMC (2CMC-TP) or 2CMA (2CMA-TP) with the natural substrates, CTP and ATP. Both 2CMA-TP and 2CMC-TP were shown to inhibit the transcriptional activity of purified RV-SA11 DLPs with an EC 50 of 10.8 ± 2.1 and 5.5 ± 2.7 µM, respectively ( Figure 2B ). The inhibitory effect of 2CMA-TP against the MNV RdRp was assessed following the synthesis of dsRNA from a single-stranded poly(U) template. 2CMA-TP inhibited the MNV RdRp activity in a dose-dependent manner, with an IC 50 of 3.1 ± 0.4 µM ( Figure 2C ), which is comparable to the inhibitory activity of 2CMC-TP against the human and mouse norovirus RdRps [11] .
DISCUSSION
Despite the availability of rotavirus vaccines, viral diarrhea remains a major cause of childhood morbidity and mortality, and has a serious global economic impact due to direct health (1) virus-induced cytopathic effect (CPE) reduction assay using methylene blue staining and (2) viral RNA levels using reverse transcription quantitative polymerase chain reaction (RT-qPCR). Potential adverse effects on the host cells were assessed in parallel and quantified by an MTS assay. Results are mean (± SEM) of 7-9 independent experiments for the CPE assay and of 3-4 independent experiments (± SEM) for the viral RNA and cytotoxicity. B, Antiviral activity of 7-deaza-2′-C-methyladenosine (7DMA) against the human Norwalk replicon was quantified by RT-qPCR. Intracellular RNA loads are represented by relative genome quantification of the Norwalk replicon versus β-actin. Dotted lines represent 50% and 90% reduction of the relative Norwalk replicon RNA levels. Results are mean (± SEM) of 5 independent experiments. C, The antiviral activity of 7-deaza-2′-C-methyladenosine (7DMA) against porcine sapovirus was quantified by (1) virus-induced CPE reduction assay using an MTS assay and (2) viral RNA levels using RT-qPCR. Potential adverse effects on the host cells were assessed in parallel and quantified by an MTS assay. Results are mean (± SEM) of 7-10 independent experiments for the CPE assay and of 3-5 independent experiments for the viral RNA and cytotoxicity.
system costs and productivity losses. There are still no specific antiviral drugs available against viral diarrhea. We previously reported on the in vitro and in vivo antiviral efficacy of 2CMC against human and murine norovirus [8] [9] [10] . We here assessed the antiviral effect of 7DMA; this analogue was shown to reduce the viral loads in HCV-infected chimpanzees [12] . 7DMA has a favorable safety profile and oral bioavailability, but it has not been further developed. Few molecules have been reported to inhibit the replication of rotaviruses [13] . Despite dsRNA viruses having a different genome organization and replication strategy than (+)ssRNA viruses [14] , we made the surprising observation that 2CMC and 7DMA also inhibit the in vitro replication of RV and act directly on the RdRp of both rota-and noroviruses. The effect of nitazoxanide in norovirus-infected patients and its proposed use for childhood diarrhea is controversial [5, 6] . In clinical trials, no reduction in viral RNA levels or significant impact on vomiting and fever were reported. We detected no antiviral effect of tizoxanide against MNV (in line with [15] ) indicating that tizoxanide cannot inhibit all noroviruses. Against rotaviruses we observed a short-lived effect of tizoxanide; this weak inhibition was reported earlier [7] . 2′-C-methyl nucleosides are direct-acting antivirals whose inhibitory effect, as we demonstrate, markedly surpasses that of nitazoxanide. Their effect is extended to sapovirus, another calicivirus that causes viral diarrhea in children. Possibly, these nucleoside analogues may also inhibit human astroviruses, which have a (+)ssRNA genome akin to caliciviruses; an inhibitory activity against (+) ssRNA picornaviruses has already been demonstrated. To assess the in vivo antirotavirus effect of these nucleosides, we infected adult mice of various strains (interferon-α/β [IFN-α/β] and IFN-γ receptor-deficient AG129, IFN-λ receptor-1 knock-out [Ifnlr1 −/− ] C57/BL6, and severe combined immunodeficiency) with different rotavirus strains (RV-ST3, RV-SA11, and rhesus rotavirus), intraperitoneally and/or orally, but no robust replication could be detected. Establishing an adult (human) rotavirus mouse model would be of great value for pharmacological in vivo studies of antirotavirus molecules.
When developing a highly potent and selective antiviral for the treatment of viral diarrhea, 2 important aspects need to be considered. Because signs and symptoms of viral diarrhea are similar, accurate and specific laboratory diagnostics are necessary, being currently available at affordable costs. Second, the time window; that is the earlier antiviral treatment is started, the greater the chance for success in preventing/treating (severe) disease. Furthermore, antivirals could be used prophylactically during an outbreak, for example in a hospital setting, to rapidly contain the spread of the virus and to prevent transmission to those in close contact with infected individuals.
In conclusion, our findings demonstrate that a syndrome-related broad-spectrum antiviral drug may be feasible; the potency and broad-spectrum activity of these 2′-C-methyl nucleosides can be further improved to develop one antiviral drug, which is highly potent, has a high barrier to resistance (like 2′-C-methyl nucleosides), and that directly targets the most common viral agents of diarrhea. Such antiviral would be of great value: (1) to treat patients who are at high risk for complications (dehydration, immunocompromised, not vaccinated for rotavirus, malnourished); (2) for those who have severe and prolonged infections; (3) to contain extensive outbreaks; and (4) to be armed when new viral strains emerge if the current rotavirus vaccines are not (sufficiently) protective.
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